![](https://endpts.com/wp-content/uploads/2024/02/Wolfgang-Wienand.jpg)
Wolfgang Wienand, Siegfried CEO
Competitor manufacturers could benefit from Novo’s acquisition of Catalent, Siegfried CEO says
Pharma companies could turn away from Catalent on the back of its $16.5 billion acquisition by Novo Holdings, which would allow for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.